You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥(02196.HK)擬最高2.5億人幣收購葛蘭素史克製藥(蘇州)
阿思達克 07-09 07:51

復星醫藥(02196.HK)(600196.SH)公布,公司控股子公司重慶藥友擬以不超過2.5億元人民幣(下同),受讓葛蘭素史克製藥(蘇州)有限公司100%股權。

如股權轉讓完成,公司將通過目標公司持有用於治療慢性乙型肝炎的拉米夫定片(規格:0.1g)的藥品註冊批件及其生產設施的生產許可證、GMP證書等。

目標公司核心產品拉米夫定片主要應用於抗病毒領域,對乙肝病毒具有較強的抑制作用,與重慶藥友現有產品治療領域具有較強協同性。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account